Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bicycle Therapeutics (BCYC) Net Cash Flow (2018 - 2026)

Bicycle Therapeutics (BCYC) has disclosed Net Cash Flow for 9 consecutive years, with -$66.7 million as the latest value for Q1 2026.

  • For Q1 2026, Net Cash Flow rose 23.36% year-over-year to -$66.7 million; the TTM value through Mar 2026 reached -$231.8 million, down 169.04%, while the annual FY2025 figure was -$252.2 million, 171.27% down from the prior year.
  • Net Cash Flow hit -$66.7 million in Q1 2026 for Bicycle Therapeutics, down from -$19.9 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $504.6 million in Q2 2024 and bottomed at -$87.0 million in Q1 2025.
  • Average Net Cash Flow over 5 years is $7.2 million, with a median of -$33.1 million recorded in 2022.
  • Year-over-year, Net Cash Flow crashed 1200.46% in 2022 and then soared 2780.59% in 2023.
  • Bicycle Therapeutics' Net Cash Flow stood at -$25.9 million in 2022, then crashed by 81.5% to -$47.0 million in 2023, then skyrocketed by 79.64% to -$9.6 million in 2024, then crashed by 108.5% to -$19.9 million in 2025, then tumbled by 234.55% to -$66.7 million in 2026.
  • According to Business Quant data, Net Cash Flow over the past three periods came in at -$66.7 million, -$19.9 million, and -$71.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.